| Business Summary | | Equidyne
Corporation,
formerly
American
Electromedics
Corp.,
is
engaged
in
the
development,
manufacture
and
sale
of
needle-free
drug
delivery
systems
worldwide,
excluding
the
European
Community.
The
Company's
current
primary
focus
is
on
the
marketing,
selling
and
continuing
development
of
the
INJEX
needle-free
drug
injection
system.
This
system
consists
of
a
hand-held,
spring-powered
device
that
injects
drugs
from
a
needle-free
syringe
through
the
skin
as
a
narrow,
high-pressure
stream
of
liquid.
The
INJEX
System
eliminates
the
need
to
pierce
skin
with
a
sharp
needle
thus
eliminating
the
risk
of
potentially
contaminated
needle
stick
incidents
and
the
resulting
blood-borne
pathogen
transmission. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Equidyne
Corporation
is
engaged
in
developing,
manufacturing
and
selling
of
needle-free
drug
delivery
systems
worldwide,
excluding
the
European
Community.
For
the
nine
months
ended
4/30/01,
net
sales
decreased
73%
to
$219
thousand.
Net
income
applicable
to
Common
totalled
$18
million,
up
from
$7.3
million.
Results
reflect
the
absence
of
Rosch
AG's
sales,
offset
by
a
$40.3
million
gain
on
the
sale
of
Rosch
AG
capital
stock. | More
from
Market Guide: Significant
Developments |
| | |
| Position | James Gavin, III, M.D., Ph.D., 55 | Interim
Chairman | Jeffery Weinress | CFO | Coburn Pharr | VP-Operations |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|